AbbVie (ABBV) announced that under the Priority Review process, Health Canada approved Elahere, an antibody-drug conjugate, for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Elahere is the first and only Health Canada approved antibody-drug conjugate targeting FRalpha, the company added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Promising Study on NSCLC Treatment: A Potential Game Changer
- AbbVie’s Promising Study on ABBV-453 for Multiple Myeloma: A Potential Game-Changer
- AbbVie’s ABBV-324 Study: A New Hope for Cancer Treatment?
- AbbVie’s Promising Phase 2 Study on Telisotuzumab Vedotin for NSCLC
- AbbVie’s Pediatric Bipolar Disorder Study: A Potential Game-Changer?